{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=16", "query": { "condition": "Refractory Malignancy", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 5765, "total_pages": 577, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T12:04:08.598Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006021", "title": "Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "ascorbic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 22, "start_date": "2000-06", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 4, "location_summary": "Miami, Florida • Miami Beach, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006021" }, { "nct_id": "NCT02103335", "title": "Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma in Relapse", "Refractory Multiple Myeloma", "Multiple Myeloma" ], "interventions": [ { "name": "pomalidomide", "type": "DRUG" }, { "name": "marizomib", "type": "DRUG" }, { "name": "low-dose dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2014-06-05", "completion_date": "2016-11-30", "has_results": false, "last_update_posted_date": "2017-11-22", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 4, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02103335" }, { "nct_id": "NCT01485835", "title": "A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ganetespib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-01", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 8, "location_summary": "Denver, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485835" }, { "nct_id": "NCT01838395", "title": "Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ara-C", "type": "DRUG" }, { "name": "BL-8040", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2013-04", "completion_date": "2023-07-20", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 5, "location_summary": "Jacksonville, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838395" }, { "nct_id": "NCT05537766", "title": "Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Waldenstrom Macroglobulinemia", "Relapsed/Refractory Richter Transformation", "Relapsed/Refractory Burkitt Lymphoma", "Relapsed/Refractory Hairy Cell Leukemia" ], "interventions": [ { "name": "Brexucabtagene Autoleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2022-11-01", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 12, "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05537766" }, { "nct_id": "NCT01034553", "title": "Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Aurora A kinase inhibitor MLN8237", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2010-02", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-05-25", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01034553" }, { "nct_id": "NCT00006045", "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "lintuzumab", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Facet Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 40, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 29 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006045" }, { "nct_id": "NCT00768339", "title": "A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, B-Cell" ], "interventions": [ { "name": "AEG35156 antisense IV infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aegera Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2008-09", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-07-13", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 4, "location_summary": "Burbank, California • Valhalla, New York • Cleveland, Ohio + 1 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Valhalla", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768339" }, { "nct_id": "NCT01364051", "title": "Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Refractory Malignant Solid Neoplasm", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2011-05-25", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364051" }, { "nct_id": "NCT07003295", "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Glofitamab", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-07-08", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-11T12:04:08.598Z", "location_count": 11, "location_summary": "Duarte, California • Atlanta, Georgia • Lexington, Kentucky + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07003295" } ] }